

Michele Dal-Bo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1757956/publications.pdf>

Version: 2024-02-01

113
papers

3,128
citations

182225

30
h-index

198040

52
g-index

113
all docs

113
docs citations

113
times ranked

4085
citing authors

#	ARTICLE	IF	CITATIONS
1	Machine Learning Application in a Phase I Clinical Trial Allows for the Identification of Clinical Biomolecular Markers Significantly Associated With Toxicity. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 686-696.	2.3	8
2	Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19. <i>International Journal of Infectious Diseases</i> , 2021, 104, 441-451.	1.5	14
3	A New Epigenetic Model to Stratify Glioma Patients According to Their Immunosuppressive State. <i>Cells</i> , 2021, 10, 576.	1.8	7
4	Nanoparticles-Based Oligonucleotides Delivery in Cancer: Role of Zebrafish as Animal Model. <i>Pharmaceutics</i> , 2021, 13, 1106.	2.0	7
5	Characterization of Thermoresponsive Poly-N-Vinylcaprolactam Polymers for Biological Applications. <i>Polymers</i> , 2021, 13, 2639.	2.0	20
6	Role of Virus-Related Chronic Inflammation and Mechanisms of Cancer Immune-Suppression in Pathogenesis and Progression of Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 4387.	1.7	15
7	A Novel Epigenetic Machine Learning Model to Define Risk of Progression for Hepatocellular Carcinoma Patients. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1075.	1.8	6
8	<i>SF3B1</i>-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation. <i>Haematologica</i> , 2021, 106, 3125-3135.	1.7	12
9	Thermoresponsive Chitosan-Grafted-Poly(N-vinylcaprolactam) Microgels via Ionotropic Gelation for Oncological Applications. <i>Pharmaceutics</i> , 2021, 13, 1654.	2.0	9
10	Chitosan-Based Biocompatible Copolymers for Thermoresponsive Drug Delivery Systems: On the Development of a Standardization System. <i>Pharmaceutics</i> , 2021, 13, 1876.	2.0	10
11	HIF-1 α is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 1042-1054.	1.7	39
12	A TGF- β 2 associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 156, 233-242.	0.6	5
13	The Dual Role of the Liver in Nanomedicine as an Actor in the Elimination of Nanostructures or a Therapeutic Target. <i>Journal of Oncology</i> , 2020, 2020, 1-15.	0.6	33
14	Glucose Metabolism and Oxidative Stress in Hepatocellular Carcinoma: Role and Possible Implications in Novel Therapeutic Strategies. <i>Cancers</i> , 2020, 12, 1668.	1.7	54
15	A Novel Comprehensive Clinical Stratification Model to Refine Prognosis of Glioblastoma Patients Undergoing Surgical Resection. <i>Cancers</i> , 2020, 12, 386.	1.7	13
16	Biallelic BIRC3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease. <i>British Journal of Haematology</i> , 2019, 185, 156-159.	1.2	9
17	New Insight into Therapies Targeting Angiogenesis in Hepatocellular Carcinoma. <i>Cancers</i> , 2019, 11, 1086.	1.7	41
18	A Pan-Cancer Approach to Predict Responsiveness to Immune Checkpoint Inhibitors by Machine Learning. <i>Cancers</i> , 2019, 11, 1562.	1.7	31

#	ARTICLE	IF	CITATIONS
19	Novel immunotherapeutic approaches for hepatocellular carcinoma treatment. Expert Review of Clinical Pharmacology, 2019, 12, 453-470.	1.3	28
20	A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines. Haematologica, 2019, 104, e410-e414.	1.7	5
21	KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival. Leukemia, 2019, 33, 2111-2115.	3.3	21
22	Expression of the transcribed ultraconserved region 70 and the related long non-coding RNA AC092652.202 has prognostic value in Chronic Lymphocytic Leukaemia. British Journal of Haematology, 2019, 184, 1045-1050.	1.2	10
23	A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial. Haematologica, 2018, 103, 849-856.	1.7	21
24	Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia. Journal of Experimental Medicine, 2018, 215, 681-697.	4.2	65
25	NOTCH1 mutational status in chronic lymphocytic leukaemia: clinical relevance of subclonal mutations and mutation types. British Journal of Haematology, 2018, 182, 597-602.	1.2	22
26	NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF- κ B pathways. Leukemia, 2018, 32, 654-662.	3.3	31
27	Regulation of HIF-1 α in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role as a Therapeutic Target. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S214.	0.2	0
28	SF3B1 Mutations Associate with Low CD20 Expression in CLL: Another NOTCH1-Dependent Mechanism?. Blood, 2018, 132, 1838-1838.	0.6	0
29	KRAS, NRAS and BRAF Mutations Are Highly Enriched in TR12 Chronic Lymphocytic Leukemia and Are Associated to Shorter Time to First Treatment. Blood, 2018, 132, 3113-3113.	0.6	0
30	Mutations in the 3' untranslated region of NOTCH1 are associated with low CD20 expression levels chronic lymphocytic leukemia. Haematologica, 2017, 102, e305-e309.	1.7	18
31	NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components. Leukemia, 2017, 31, 2407-2415.	3.3	52
32	Mutational status of IGHV is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia. Haematologica, 2017, 102, e443-e446.	1.7	11
33	INSIDE-OUT VLA-4 INTEGRIN ACTIVATION IS MAINTAINED IN IBRUTINIB-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA EXPRESSING CD49D: CLINICAL RELEVANCE. Hematological Oncology, 2017, 35, 109-110.	0.8	1
34	Low-dose radiotherapy in diffuse large B-cell lymphoma. Hematological Oncology, 2017, 35, 472-479.	0.8	9
35	CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia. Leukemia, 2016, 30, 2011-2018.	3.3	41
36	Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia. Haematologica, 2016, 101, 77-85.	1.7	53

#	ARTICLE	IF	CITATIONS
37	A new approach for the treatment of CLL using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles. <i>Nano Research</i> , 2016, 9, 537-548.	5.8	17
38	NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation. <i>Leukemia</i> , 2016, 30, 182-189.	3.3	74
39	Persistent CD49d engagement in circulating CLL cells: a role for blood-borne ligands?. <i>Leukemia</i> , 2016, 30, 513-517.	3.3	3
40	Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia. <i>Drugs of Today</i> , 2016, 52, 249.	0.7	18
41	Functional and Clinical Significance of the Integrin Alpha Chain CD49d Expression in Chronic Lymphocytic Leukemia. <i>Current Cancer Drug Targets</i> , 2016, 16, 659-668.	0.8	11
42	Low Bax/Bcl-2 Ratio and NOTCH1 Mutations Represent Powerful and Synergistic Adverse Prognostic Factors within Trisomy 12 Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2016, 128, 3204-3204.	0.6	0
43	Mutations at 3' Untranslated Region (3'UTR) of NOTCH1 Are Associated with Low CD20 Expression Levels in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 306-306.	0.6	0
44	Lack of Prognostic Significance of the Conventional and Novel Prognostic Markers in Trisomy 12 Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2016, 128, 4354-4354.	0.6	0
45	HIF-1 \uparrow Upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target. <i>Blood</i> , 2016, 128, 305-305.	0.6	0
46	Comprehensive Characterization of NOTCH1 Mutational Status in Chronic Lymphocytic Leukemia: Clinical Relevance of Subclonal Mutations and Mutation Types. <i>Blood</i> , 2016, 128, 3195-3195.	0.6	0
47	The B-Cell Receptor Signaling Inhibitor Molecules CD305 and CD307b Are Markers of Favorable Prognosis in Chronic Lymphocytic Leukemia with Both Mutated and Unmutated IGHV Gene Status. <i>Blood</i> , 2016, 128, 4358-4358.	0.6	1
48	The MYC\uparrow/miR-17-92</i> axis in lymphoproliferative disorders: A common pathway with therapeutic potential. <i>Oncotarget</i> , 2015, 6, 19381-19392.	0.8	51
49	The Kr \uparrow 4ppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. <i>Leukemia</i> , 2015, 29, 503-507.	3.3	84
50	The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells. <i>Oncotarget</i> , 2015, 6, 19102-19117.	0.8	18
51	Retention of inside-out VLA-4 Integrin Activation upon B-Cell Receptor Triggering in in-Vitro and in-Vivo Ibrutinib Treated Chronic Lymphocytic Leukemia Cells: Clinical Implication. <i>Blood</i> , 2015, 126, 1708-1708.	0.6	0
52	The Concomitant High Expression of the B-Cell Receptor Signaling Inhibitor Molecules CD150, CD305, and CD307b Predicts Longer Overall Survival in the Context of Low-Risk Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 1720-1720.	0.6	0
53	Apoptosis and Proliferation Synergistically Determine Overall Survival in Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2015, 126, 1718-1718.	0.6	0
54	Identification of a Novel Gene Expression Signature in Mantle Cell Lymphoma from the Fondazione Italiana Linfomi (FIL)-MCL-0208 Trial: A Focus on the B Cell Receptor Pathway. <i>Blood</i> , 2015, 126, 701-701.	0.6	0

#	ARTICLE	IF	CITATIONS
55	CD49d expression identifies a chronic-lymphocytic leukemia subset with high levels of mobilized circulating CD34+ hemopoietic progenitors cells. <i>Leukemia</i> , 2014, 28, 705-708.	3.3	10
56	Potential therapeutic role of antagomiR17 for the treatment of chronic lymphocytic leukemia. <i>Journal of Hematology and Oncology</i> , 2014, 7, 79.	6.9	22
57	Ibrutinib-naïve chronic lymphocytic leukemia lacks Bruton tyrosine kinase mutations associated with treatment resistance. <i>Blood</i> , 2014, 124, 3831-3833.	0.6	27
58	Microenvironmental Interactions in Chronic Lymphocytic Leukemia: The Master Role of CD49d. <i>Seminars in Hematology</i> , 2014, 51, 168-176.	1.8	32
59	NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment. <i>Annals of Hematology</i> , 2014, 93, 1765-1774.	0.8	34
60	NOTCH1 Mutations Are Associated with Low CD20 Expression in Chronic Lymphocytic Leukemia: Evidences for a NOTCH1-Mediated Epigenetic Regulatory Mechanism. <i>Blood</i> , 2014, 124, 296-296.	0.6	5
61	NOTCH1 Mutations Are Associated with High CD49d Expression in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2014, 124, 1978-1978.	0.6	0
62	Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. <i>Blood</i> , 2013, 121, 1403-1412.	0.6	420
63	Clinical significance of c.7544â€“7545 del<sc>CT </sc><i><sc>NOTCH</sc>1</i> mutation in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2013, 160, 415-418.	1.2	14
64	Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application. <i>Journal of Hematology and Oncology</i> , 2013, 6, 83.	6.9	14
65	<i><sc>ARHGDI</sc></i>, a mutant <sc>TP</sc>53â€“associated Rho <sc>GDP</sc> dissociation inhibitor, is overâ€“expressed in gene expression profiles of <i><sc>TP</sc>53</i> disrupted chronic lymphocytic leukaemia cells. <i>British Journal of Haematology</i> , 2013, 161, 596-599.	1.2	3
66	Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. <i>Blood</i> , 2013, 121, 4902-4905.	0.6	113
67	CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism. <i>Blood</i> , 2013, 122, 3317-3321.	0.6	48
68	Genomic Aberrations Dramatically Improve The Strong Prognostic Impact Of IGHV Mutational Status In Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2013, 122, 1370-1370.	0.6	1
69	The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells. <i>Leukemia</i> , 2012, 26, 1301-1312.	3.3	78
70	Microenvironmental Interactions in Chronic Lymphocytic Leukemia: Hints for Pathogenesis and Identification of Targets for Rational Therapy. <i>Current Pharmaceutical Design</i> , 2012, 18, 3323-3334.	0.9	17
71	CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study. <i>Haematologica</i> , 2012, 97, 279-287.	1.7	32
72	The miR-17âˆ“92 family regulates the response to Toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes. <i>Leukemia</i> , 2012, 26, 1584-1593.	3.3	77

#	ARTICLE	IF	CITATIONS
73	CD49d Is Overexpressed in Trisomy 12 Chronic Lymphocytic Leukemia by an Epigenetic-Dependent Transcriptional Control. <i>Blood</i> , 2012, 120, 929-929.	0.6	1
74	Clinical Significance of NOTCH1 mutations in Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2012, 120, 2870-2870.	0.6	0
75	Clinical Significance of 13q14 Number of Deleted Cells in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012, 120, 4581-4581.	0.6	0
76	Circulating CLL Cells Expressing CD49d Display a Phospho-Proteomic Profile Consistent with a Constitutive Receptor Engagement by Blood-Borne Ligands. <i>Blood</i> , 2012, 120, 930-930.	0.6	0
77	The Elastin Microfibril Interfacer-1 (EMILIN-1) Is a Ligand for CD49d in Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 2012, 120, 1772-1772.	0.6	0
78	Bâ€cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the <i>IGHV3</i> subgroup gene usage. <i>British Journal of Haematology</i> , 2011, 153, 3-14.	1.2	30
79	13q14 Deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2011, 50, 633-643.	1.5	67
80	Molecular and clinical features of chronic lymphocytic leukemia with stereotyped B-cell receptors in a Ukrainian cohort. <i>Leukemia and Lymphoma</i> , 2010, 51, 822-838.	0.6	9
81	<i>IGHD3â€3</i> fails to behave as unfavourable prognostic marker in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2010, 149, 299-302.	1.2	1
82	<i>MDM4 (MDMX)</i> is overexpressed in chronic lymphocytic leukaemia (CLL) and marks a subset of p53^{wildâ€type} CLL with a poor cytotoxic response to Nutlinâ€3. <i>British Journal of Haematology</i> , 2010, 150, 237-239.	1.2	27
83	The expression levels of the pro-apoptotic XAF-1 gene modulate the cytotoxic response to Nutlin-3 in B chronic lymphocytic leukemia. <i>Leukemia</i> , 2010, 24, 480-483.	3.3	7
84	Expression of Mutated <i>IGHV3-23</i> Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological Features. <i>Clinical Cancer Research</i> , 2010, 16, 620-628.	3.2	44
85	Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells. <i>Journal of Translational Medicine</i> , 2010, 8, 23.	1.8	19
86	13q14 Chromosome Deletion Size and Number of Deleted Cells Influence Prognosis In Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010, 116, 3578-3578.	0.6	0
87	Exposure of B Cell Chronic Lymphocytic Leukemia (B-CLL) Cells to Nutlin-3 Induces a Characteristic Gene Expression Profile, which Correlates with Nutlin-3-Mediated Cytotoxicity (Supplementary Table). <i>Current Cancer Drug Targets</i> , 2009, 9, 510-518.	0.8	11
88	CD38/CD31, the CCL3 and CCL4 Chemokines, and CD49d/Vascular Cell Adhesion Molecule-1 Are Interchained by Sequential Events Sustaining Chronic Lymphocytic Leukemia Cell Survival. <i>Cancer Research</i> , 2009, 69, 4001-4009.	0.4	153
89	Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study. <i>British Journal of Haematology</i> , 2009, 144, 492-506.	1.2	106
90	Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance. <i>Journal of Translational Medicine</i> , 2009, 7, 76.	1.8	41

#	ARTICLE	IF	CITATIONS
91	Are surrogates of IGHV gene mutational status useful in B-cell chronic lymphocytic leukemia? The example of Septin-10. <i>Leukemia</i> , 2008, 22, 224-226.	3.3	8
92	Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. <i>Blood</i> , 2008, 111, 865-873.	0.6	226
93	Comprehensive characterization of IGHV3-21 ϵ^{H} expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study. <i>Blood</i> , 2007, 109, 2989-2998.	0.6	62
94	Telomerase expression in B-cell chronic lymphocytic leukemia predicts survival and delineates subgroups of patients with the same igVH mutation status and different outcome. <i>Leukemia</i> , 2007, 21, 965-972.	3.3	57
95	Molecular and Clinical Features of B Cell Chronic Lymphocytic Leukemia (CLL) Carrying Stereotyped B Cell Receptors: An Italian Experience.. <i>Blood</i> , 2007, 110, 3089-3089.	0.6	0
96	Surface-antigen expression profiling of B cell chronic lymphocytic leukemia: from the signature of specific disease subsets to the identification of markers with prognostic relevance. <i>Journal of Translational Medicine</i> , 2006, 4, 11.	1.8	9
97	B-Cell Chronic Lymphocytic Leukemia. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2006, 14, 154-160.	0.6	2
98	CD49d in B-cell chronic lymphocytic leukemia: correlated expression with CD38 and prognostic relevance. <i>Leukemia</i> , 2006, 20, 523-525.	3.3	51
99	Reply to Pittner et al.. <i>Leukemia</i> , 2006, 20, 528-529.	3.3	10
100	Immunophenotypic characterization of IgVH3-72 B-cell chronic lymphocytic leukaemia (B-CLL). <i>Leukemia Research</i> , 2006, 30, 1197-1199.	0.4	17
101	ZAP-70 expression in B-cell chronic lymphocytic leukemia: Evaluation by external (isotypic) or internal (T/NK cells) controls and correlation with IgVH mutations. <i>Cytometry Part B - Clinical Cytometry</i> , 2006, 70B, 284-292.	0.7	38
102	A scoring system based on the expression of six surface molecules allows the identification of three prognostic risk groups in B-cell chronic lymphocytic leukemia. <i>Journal of Cellular Physiology</i> , 2006, 207, 354-363.	2.0	49
103	Gene Expression Profiling (GEP) of CD38-Expressing/Unmutated B-Cell Chronic Lymphocytic Leukemia (B-CLL) Cells by Using a Statistical Approach Suitable for Analysis of Unbalanced Datasets.. <i>Blood</i> , 2006, 108, 2089-2089.	0.6	0
104	Mutational status of IgVH genes in B-cell chronic lymphocytic leukemia and prognosis: percent mutations or antigen-driven selection?. <i>Leukemia</i> , 2005, 19, 1490-1492.	3.3	23
105	Surface-antigen expression profiling (SEP) in B-cell chronic lymphocytic leukemia (B-CLL): Identification of markers with prognostic relevance. <i>Journal of Immunological Methods</i> , 2005, 305, 20-32.	0.6	17
106	Signature of B-CLL with different prognosis by Shrunken centroids of surface antigen expression profiling. <i>Journal of Cellular Physiology</i> , 2005, 204, 113-123.	2.0	30
107	Activation-Induced Cytidine Deaminase and CD38 Expression in B-Cell Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma and Myeloma</i> , 2005, 6, 251-252.	1.4	3
108	Mutational Status of IgVH Genes in B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Prognosis: Percent Mutations or Evaluation of Antigen-Driven Selection?. <i>Blood</i> , 2005, 106, 2106-2106.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Analysis of IgVH gene mutations in B-Cell chronic lymphocytic leukaemia according to antigen-driven selection identifies subgroups with different prognosis and usage of the canonical somatic hypermutation machinery. British Journal of Haematology, 2004, 126, 29-42.	1.2	54
110	Mutational Status of IgVH Genes Consistent with Antigen-Driven Selection but Not Percent of Mutations Has Prognostic Impact in B-Cell Chronic Lymphocytic Leukemia. Clinical Lymphoma and Myeloma, 2004, 5, 123-126.	2.1	9
111	Error-Prone DNA Polymerases iota and beta Are Over-Expressed in B-CLL Cells: Correlation with Specific IgVH Point-Mutations and Implication for the Pathogenesis of Intraclonal IgVH Diversification.. Blood, 2004, 104, 950-950.	0.6	1
112	Immunophenotypic clustering of B-Cell chronic lymphocytic leukemia (B-CLL) reveals a good prognosis disease subset characterized by the coordinated over-expression of CD62L, CD54, CD49c, CD25 And CD55. Journal of Clinical Oncology, 2004, 22, 6567-6567.	0.8	1
113	B-cell chronic lymphocytic leukemia. , 0, , 786-792.		0